The Motley Fool

What does this blow to Woodford Patient Capital say about investing in Neil Woodford?

Image source: Getty Images.

Shares in Woodford Patient Capital Trust (LSE: WPCT) had been picking up from their recent low, gaining 10% since 28 August.

That’s against a significant discount to net asset value (NAV) – the shares had plunged to a discount of 48% when I investigated in August. Now, investment trusts do typically trade at a discount, with a share priced at a little less than the underlying assets that the share represents. But I’d generally view a discount of around 15% or so as looking attractive, depending on the circumstances. I don’t recall ever seeing anything this big before.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...


One problem with Woodford Patient Capital is that it invests heavily in unquoted assets that are notoriously hard to value, which adds significant uncertainty to any published NAV figures. By contrast, many trusts invest exclusively in quoted equities on world stock markets, which makes the NAV much easier to calculate. In my view, trusts like that are often a great choice if you’re looking for a long-term pooled investment.

The Woodford trust has now suffered a new blow resulting in a lowering of its NAV, due to a write-down in the value of an investment picked by fund manager Neil Woodford. One of the the trust’s investments has had its valuation lowered by £42m by auditors Link Fund Solutions.

Unfortunately, investors are not yet allowed to know the name of the downgraded company for confidentiality reasons, and that’s another reason I don’t like investments in unquoted assets – with listed companies, far more is out in the open where we can all see it.


This latest hit to the Woodford trust comes less than a month after another of the firms it holds was devalued. That time it was Industrial Heat, and the downgrade hit Woodford Patient Capital to the tune of around £30m.

Subsequent to the two valuation downgrades, the trust’s NAV was restated Monday morning at 69.04p per share. Compared to 78.96p the day before the Industrial Heat news emerged, it’s down 12.6% in a little over a month.

At that level, and with the shares currently trading at 45.4p, we’re looking at a discount right now of 42.5%, which is still pretty enormous in terms of what’s usually seen with investment trusts. So is Woodford Patient Capital oversold and is it a buy?


My Motley Fool colleague G A Chester (who has been negative on Woodford Patient Capital for some time and deserves a nod for that) thinks there are still good reasons to steer clear. As he points out, Woodford is under considerable pressure to sell off a lot of unquoted investments. For one thing, he needs to clear the trust’s £150m overdraft within 12 months. Seeing an investment trust geared with borrowed money is not something I like either.

That, plus the effects of Woodford selling often the same assets within his currently gated Equity Income fund, seems very likely to lead to more valuation reductions, especially as so many of them are currently unprofitable.

I had been tempted to buy a few Woodford Patient Capital shares in the hope of a rebound, but I see enough long-term negativity that I’ve decided against it.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.